Abide Therapeutics' Series A Round

Abide Therapeutics raised a round of funding on November 18, 2011. Investors include Cardinal Partners.

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Se…

Articles about Abide Therapeutics' Series A Round: